YS Biopharma's rabies vaccine bests approved competitor in interim phase 3 readout

China’s YS Biopharma has a good feeling about a phase 3 trial of its investigational PIKA rabies vaccine if a glimpse at the interim data is anything to go by.

The biotech has been putting the vaccine, which uses YS Biopharma's PIKA adjuvant technology, up against a “globally marketed comparator” in a 4,500-participant trial in the Philippines and Pakistan.